# Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia

> **NCT00283179** · PHASE3 · COMPLETED · sponsor: **Taiwan Otsuka Pharm. Co., Ltd** · enrollment: 83 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00283179
- **Lead sponsor:** Taiwan Otsuka Pharm. Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2008-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283179, "Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00283179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*